CTOR
Citius Oncology, Inc.
NASDAQ: CTOR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$0.88
+2.31% today
Updated 2026-04-30
Market cap
$77.43M
P/E ratio
—
P/S ratio
19.63x
EPS (TTM)
$-0.31
Dividend yield
—
52W range
$0 – $6
Volume
0.3M
Citius Oncology, Inc. (CTOR) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-19.3%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+35.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-4.2%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-8.4%
2025-12-23
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-13 | $-0.06 | -200.0% | $1.18 | $1.18 | +0.0% |
| 2025-12-23 | $-0.06 | +14.3% | $1.25 | $1.15 | -8.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.02 | $-0.06 | -200.0% | $3.94M | — |
| 2025-09-30 | $-0.07 | $-0.06 | +14.3% | — | — |
| 2025-06-30 | $-0.09 | $-0.08 | +11.1% | — | — |
| 2025-03-31 | $-0.06 | $-0.11 | -83.3% | — | — |
| 2024-12-31 | $-0.06 | $-0.09 | -55.2% | — | — |
| 2024-09-30 | $-0.08 | $-0.31 | -282.4% | — | — |
| 2024-06-30 | — | $0.04 | — | — | — |
| 2024-03-31 | — | $0.07 | — | — | — |
| 2023-12-31 | — | $0.12 | — | — | — |
| 2023-09-30 | — | $0.02 | — | — | — |
| 2023-06-30 | — | $0.07 | — | — | — |
| 2023-03-31 | — | $0.07 | — | — | — |
Frequently asked questions
Has Citius Oncology, Inc. beaten earnings estimates?
Citius Oncology, Inc. has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -19.3% over the last 3 quarters.
How does CTOR stock react to earnings?
CTOR stock has moved an average of -4.2% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.